Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 48 clinical trials
Denosumab in Subjects With Giant Cell Rich Tumors of Bone

An open-label, multi-center, phase 2 study of the efficacy of denosumab in subjects with giant cell rich tumors of bone. The population will consist of subjects with the following tumor types

  • 0 views
  • 05 Mar, 2022
  • 1 location
The Optimal Sequential Therapy After Long Term Denosumab Treatment

This study intends to investigate whether Alendronate and Zoledronate can prevent bone mineral density loss after long-term treatment with Denosumab.

alendronate
zoledronate
denosumab
  • 0 views
  • 02 Nov, 2021
  • 1 location
Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery

Bariatric surgery leads to bone loss and increases fracture risk. This study evaluates whether denosumab can prevent the high-turnover bone loss that occurs after Roux-en-Y Gastric Bypass (RYGB

roux-en-y
gastric bypass
denosumab
zoledronic acid
gastrectomy
  • 1 views
  • 27 Apr, 2022
  • 1 location
Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours (Dern)

The aim of the present investigation is to test of the modulation obtained with denosumab as "priming" therapy before the start of chemotherapy and as concurrent therapy in a population of first

absolute neutrophil count
carcinoma
epstein-barr virus deoxyribonucleic acid
combination therapy
chemotherapy regimen
  • 1 views
  • 27 Feb, 2022
  • 1 location
A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

This research study is studying a possible therapy as a possible treatment for the consequences of Multiple Myeloma with renal insufficiency.

vasectomy
monoclonal antibodies
bisphosphonate
calcium
plasmacytoma
  • 2 views
  • 27 Jan, 2022
  • 7 locations
Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer

This multicenter, randomized, comparative study will evaluate the efficacy of denosumab to prevent the adjuvant therapy of aromatase inhibitors-induced loss of bone mineral density (BMD) in

progesterone receptor
mastectomy
bisphosphonate
letrozole
adjuvant therapy
  • 5 views
  • 18 Apr, 2022
  • 1 location
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI

The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with

bone mineral density
romosozumab
denosumab
  • 0 views
  • 26 Dec, 2021
  • 2 locations
The Optimal Long Term Treatment Strategy of Anti-resorptive Medications---The Extension of Denosumab Sequential Therapy

This study is to investigate whether the alternating use of Prolia (Denosumab) and Aclasta (Zoledronic acid) can continue to increase bone density.

zoledronic acid
zoledronate
denosumab
  • 0 views
  • 01 Nov, 2021
  • 1 location
Effects of Denosumab on Bone Fusion in Osteoporotic Patients After Lumbar Fusion

reason for spinal fusion failure, implant fixation failure, and vertebral compression fractures above or below the fusion sites. Denosumab is a human monoclonal antibody against RANKL, it inhibits

denosumab
bone mineral density
osteoporosis
RANKL
x-ray absorptiometry
  • 0 views
  • 22 Mar, 2022
  • 1 location
Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study

will be attenuated more in those who switch from denosumab to "late" zoledronic acid (9 months after last denosumab dose) compared to participants randomized to "early" zoledronic acid (6 months after

  • 0 views
  • 26 Dec, 2021
  • 1 location